Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report.
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report.
复制标题
DOI：
10.1159/000443662
复制
发表时间：
2016-01
影响因子：
0.8
通讯作者：
Gotoh M
中科院分区：
文献类型：
--
作者：
Osugi J;Owada Y;Yamaura T;Muto S;Okabe N;Matsumura Y;Higuchi M;Suzuki H;Gotoh M
克唑替尼是第一个临床可用的间变性淋巴瘤激酶 (ALK) 基因重排抑制剂，通常具有良好的耐受性。相比之下，克唑替尼引起的中性粒细胞减少症是常见的 3 级或 4 级不良事件。在这种情况下，对于一些患有严重中性粒细胞减少症的患者可能需要中断克唑替尼治疗并减少剂量。然而，目前有关严重中性粒细胞减少症的临床经验和治疗的信息有限。本报告描述了通过减少 ALK 阳性非小细胞肺癌患者克唑替尼剂量成功治疗克唑替尼引起的中性粒细胞减少症。
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.